Where Travere Therapeutics Stands With Analysts
Portfolio Pulse from Benzinga Insights
Travere Therapeutics (NASDAQ:TVTX) has received mixed analyst ratings in the last quarter, with 3 bullish, 5 somewhat bullish, and 3 indifferent ratings. The average 12-month price target among 11 analysts is $16.91, with a high of $30.00 and a low of $7.00. This target has decreased by 41.69% from the previous average of $29.00. Analysts base their ratings on financial predictions and company performance metrics.
November 20, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Travere Therapeutics has a current average analyst price target of $16.91, which is a significant decrease from the previous target of $29.00. The mixed ratings indicate uncertainty among analysts.
The decrease in the average price target and the mixed ratings from analysts could lead to uncertainty in the short term for TVTX's stock price. However, the absence of bearish ratings and the presence of bullish and somewhat bullish ratings might balance the sentiment, leading to a neutral impact on the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100